
|Articles|February 3, 2005
FDA approves gene-based test for bladder cancer
Abbott's UroVysion DNA probe assay has been approved by the FDA for use as an aid in initial diagnosis of bladder cancer in patients with hematuria and suspected of having bladder cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
3
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











